Infinant Health
This company develops microbiome-based therapeutics to improve infant gut health and prevent conditions like necrotizing enterocolitis. Their drugs, currently undergoing clinical trials, aim to support healthy immune system function in infants, particularly preterm babies.
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$55MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
In developed countries, modern medical practices have led to a significant reduction in the presence of beneficial bacteria, specifically *B. infantis*, in infant guts, impacting immune system development. This absence can increase the risk of conditions like necrotizing enterocolitis (NEC), especially in preterm infants.
Solution
Infinant Health develops microbiome-based therapeutics designed to restore and support a healthy infant gut microbiome, with a focus on *B. infantis* strains. Their lead drug candidate, INF108, is a next-generation strain specifically formulated to prevent NEC in premature infants by promoting the colonization of beneficial bacteria and reducing gut inflammation. The company's approach leverages the unique ability of certain *B. infantis* strains to metabolize human milk oligosaccharides (HMOs) in breast milk, converting them into key signaling molecules that guide healthy immune system function. By reintroducing these beneficial bacteria, Infinant Health aims to establish a foundation for better health and prevent immune-related issues early in life.
Target Audience
The primary target audience includes preterm infants at risk of developing NEC, as well as healthy, full-term infants who would benefit from improved gut microbiome composition and immune system development.
Features
- Utilizes proprietary *B. infantis* strains, including EVC001 and INF108, optimized for HMO utilization
- INF108 is specifically designed to prevent necrotizing enterocolitis (NEC) in preterm infants
- Products promote the colonization of beneficial bacteria in the infant gut
- Strains convert HMOs into key signaling molecules that support healthy immune system function
- Aims to reduce the abundance of antibiotic-resistant organisms in the infant gut
- Formulations are designed to work synergistically with breast milk to nourish and protect the baby